Genetic manipulation of donor t cells to control graft versus host disease gvhd
Download
1 / 20

Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD) - PowerPoint PPT Presentation


  • 132 Views
  • Uploaded on

Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD). Jordan Laboratory for hemato-oncology Hematology Department Eric Lammertsma - Tineke Lenstra - Hiljanne van der Meer Tom van Meerten – Samantha Hol. Contents. Introduction Approach Methods Conclusions

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD)' - fauve


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Genetic manipulation of donor t cells to control graft versus host disease gvhd
Genetic manipulation of donor T cells to control Graft versus Host disease (GvHD)

Jordan Laboratory for hemato-oncology Hematology Department

Eric Lammertsma - Tineke Lenstra - Hiljanne van der Meer

Tom van Meerten – Samantha Hol


Contents
Contents versus Host disease (GvHD)

  • Introduction

  • Approach

  • Methods

  • Conclusions

  • Discussion


Introduction
Introduction versus Host disease (GvHD)

  • Haematological malignancies

    -> Stem Cell Transplantation

    -> Complication: Graft versus Host Disease


Role of donor t cells in sct
Role of donor T-cells in SCT versus Host disease (GvHD)


Treatment of gvhd
Treatment of GvHD versus Host disease (GvHD)

  • Immunosuppressive drugs

  • Suicide gene therapy:

  • HSV-thymidine kinase with ganciclovir


Suicide gene therapy cd20 cd20
Suicide gene therapy: CD20/αCD20 versus Host disease (GvHD)

  • Transduce T-cells with CD20-gene

  • Transplant

  • T-cell depleted Hematopoeitic Stem Cells

  • CD20 T-cells

  • GvHD -> αCD20 = Rituximab


Suicide gene therapy cd20 cd201
Suicide gene therapy: CD20/αCD20 versus Host disease (GvHD)

Rituximab (CD20 antibody) + complement


FACS versus Host disease (GvHD)

SS

SS

FS

FS

Side Scatter (SSC)

Side Scatter (SSC)

Forward Scatter (FSC)

Forward Scatter (FSC)


Approach
Approach versus Host disease (GvHD)

  • Transfect Ph-ampho cells to produce virus with CD20 vector

  • Transduce CD20 DNA to human CEM cells

  • Examine the expression of CD20

  • Examine the effect of Rituximab on transduced cells


Transfection
Transfection versus Host disease (GvHD)

  • Ph-ampho cells for virus production

  • Gene variants:

  • CD20

  • CD20 wpre ic

  • CD20 wpre

  • CD20 ins9


Transfection1
Transfection versus Host disease (GvHD)

  • CD20, CD20 wpre ic and CD20 wpre transfected

  • CD20 ins9 not expressed

  • Virus harvested


Transduction
Transduction versus Host disease (GvHD)

  • CEM cells (human donor T cells)

  • Incubated with 4 virus concentrations

  • Examined CD20 expression

    (transduction efficiency)


Transduction1
Transduction versus Host disease (GvHD)

  • CD20 expression in transduced T cells


Transduction2
Transduction versus Host disease (GvHD)


Effect of rituximab
Effect of Rituximab versus Host disease (GvHD)

Rituximab (CD20 antibody) + complement


Effect of rituximab1
Effect of Rituximab versus Host disease (GvHD)

Clones

Control


Conclusions
Conclusions versus Host disease (GvHD)

  • CD20 T-cell production possible

  • Rituximab causes cell lysis ->

    independent of level of CD20 expression


Discussion
Discussion versus Host disease (GvHD)

  • No reliable negative control

  • Up to 10% CD20 T-cell survival

  • Rituximab specific for CD20 (?)

  • CD20 on human B-cells


ad